COVID-19 Vaccine Acceptance Among Pregnant Women and Mothers of Young Children Results of a Survey in 16 Countries

Skjefte, Malia; Ngirbabul, Michelle; Akeju, Oluwasefunmi; Escudero, Daniel J.; Hernández–Dı́az, Sonia; Wyszynski, Diego F.; Wu, Julia

doi:10.2139/ssrn.3759631

Cited by 21 publications

(28 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because mRNA-based vaccines are a new technology that has not been widely tested in pregnant women, it is plausible that the immune response triggered by these vaccines in pregnant women may be altered compared to the general population, increasing the need to evaluate vaccine effectiveness specifically for this subpopulation. In a previous report, confidence in vaccine effectiveness among pregnant women was mentioned as one of the strongest predictors of COVID-19 vaccine acceptance in this group 12 .…”

mentioning

confidence: 74%

See 1 more Smart Citation

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Dagan

Barda

Biron‐Shental

et al. 2021

Nat Med

Self Cite

258

234

View full text Add to dashboard Cite

mentioning

confidence: 74%

“…If vaccine effectiveness >90% was achieved, 52% of pregnant women reported that they would be willing to receive the vaccine. Furthermore, pregnant women indicated higher likelihood of vaccination with higher vaccine effectiveness 12 .…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Dagan

Barda

Biron‐Shental

et al. 2021

Nat Med

Self Cite

258

234

View full text Add to dashboard Cite

“…Although much is known about COVID-19 vaccine hesitancy among adults, [16][17][18][19][20] little is known about parental hesitancy for COVID-19 vaccines for children. 16,[21][22][23] Rhodes 21 surveyed US parents of preschool children who were pre-screened as hesitant toward childhood vaccines, noting high hesitancy about a future COVID-19 vaccine for children; parents desired information from healthcare professionals and alternative medical providers. An early study in April 2020 noted high intent to vaccinate.…”

Section: Introductionmentioning

confidence: 99%

Parents’ Intentions and Perceptions About COVID-19 Vaccination for Their Children: Results From a National Survey

et al. 2021

View full text Add to dashboard Cite

This nationally representative survey found that less than one-half of US parents are likely to have their child receive COVID-19 vaccines when they are available. What's Known on This Subject:Very little is known about parental hesitancy for COVID-19 vaccines for children. What This Study Adds:This nationally representative survey found that less than one-half of US parents are likely to have their child receive the COVID-19 vaccine when it is available.

show abstract

“…of the pregnant women reported that they would be willing to receive the vaccine. Furthermore, pregnant women indicated higher likelihood of vaccination with higher VE (8).…”

Section: Discussionmentioning

confidence: 96%

“…Since mRNA-based vaccines are a novel technology that has not been widely tested among pregnant women, it is plausible that the immune response triggered by these vaccines in pregnant women may be altered compared to the general population, increasing the need to evaluate VE speci cally for this sub-population. In a previous report, con dence in VE among pregnant women was mentioned as one of the strongest predictors of COVID-19 vaccine acceptance in this group (8). The objective of this study is thus to provide real-world VE measures in a large cohort of vaccinated pregnant women.…”

Section: Introductionmentioning

confidence: 95%

Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine in Pregnancy

Balicer

Dagan

Barda

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: As mass vaccination campaigns against COVID-19 accelerate worldwide, there remains only limited evidence regarding vaccine effectiveness (VE) among pregnant women. Pregnant women have been shown to be at risk for severe COVID-19, resulting in adverse obstetrics outcomes, and their immune system is known to undergo alterations during pregnancy. Phase III clinical trials of the approved mRNA COVID-19 vaccines excluded pregnant women, yet current guidelines encourage offering the vaccine to pregnant women. In this study, we examine data from Israel’s largest healthcare organization to evaluate the effectiveness of the BNT162b2 mRNA vaccine among pregnant women. Methods: We conducted an observational cohort study of pregnant women 16 years or older, with no history of SARS-CoV-2, who were vaccinated between December 20, 2020 and June 3, 2021. Vaccinated subjects were matched to unvaccinated controls according to a set of demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. For each outcome, VE was estimated at several periods following vaccination as one minus the risk ratio using the Kaplan–Meier estimator. Results: 10,861 vaccinated women were matched to an identical number of unvaccinated controls. Estimated VE from 7 through 28 days after the second dose was 97% (95% CI 91%-100%) for any documented infection, 96% (86-100%) for infections with documented symptoms, and 85% (32%-100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group, and no deaths were observed in either group -- insufficient incidence for estimating VE for these outcomes. Discussion: The BNT162b2 mRNA vaccine was found to have high VE among pregnant women. Since high VE has been reported as one of the strongest predictors of COVID-19 vaccine acceptance among pregnant women, the high VE estimates found in this study have the potential to increase vaccine acceptance in this group. In addition, the present VE estimates are similar to those reported in the general population for the same variants, suggesting that it may be possible to infer the VE for pregnant women from studies in the general population for both current and future variants.

show abstract

COVID-19 Vaccine Acceptance Among Pregnant Women and Mothers of Young Children Results of a Survey in 16 Countries

Cited by 21 publications

References 21 publications

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Parents’ Intentions and Perceptions About COVID-19 Vaccination for Their Children: Results From a National Survey

Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine in Pregnancy

Contact Info

Product

Resources

About